Invivyd (NASDAQ:IVVD) Receives Buy Rating from HC Wainwright

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $10.00 price target on the stock.

Several other equities analysts have also commented on IVVD. BTIG Research reaffirmed a “buy” rating and set a $10.00 target price on shares of Invivyd in a report on Tuesday, June 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Invivyd in a research note on Wednesday, April 29th. Finally, Wall Street Zen lowered shares of Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Invivyd Price Performance

Shares of IVVD opened at $0.77 on Monday. Invivyd has a 1 year low of $0.48 and a 1 year high of $3.07. The stock has a 50 day simple moving average of $1.32 and a two-hundred day simple moving average of $1.77. The firm has a market cap of $226.85 million, a P/E ratio of -2.48 and a beta of 0.63.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.05). The business had revenue of $13.74 million for the quarter, compared to analysts’ expectations of $18.04 million. Invivyd had a negative return on equity of 53.48% and a negative net margin of 138.90%. On average, equities analysts anticipate that Invivyd will post -0.5 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Invesco Ltd. raised its holdings in Invivyd by 190.6% during the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock valued at $66,000 after buying an additional 71,485 shares during the last quarter. AQR Capital Management LLC grew its holdings in Invivyd by 2,051.0% in the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock worth $249,000 after acquiring an additional 391,617 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Invivyd in the second quarter valued at about $158,000. Jane Street Group LLC purchased a new position in shares of Invivyd in the second quarter valued at about $147,000. Finally, Vanguard Group Inc. raised its stake in shares of Invivyd by 46.7% during the third quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock valued at $6,339,000 after acquiring an additional 1,834,970 shares during the last quarter. Institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.